CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round. The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm. The funding will further support the advancement of CellCentric’s novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma.
A phase IIa dose optimisation clinical study is ongoing with an all-oral triplet of inobrodib combined with pomalidomide and dexamethasone. Proceeds from the Series C financing will be used to support:
Initiation of a Phase II/III study in heavily pretreated multiple myeloma patients, with the potential to support an accelerated approval. Support development activities for a Phase III programme, to start mid-2026.
Initiation of trials starting Q2 2025, including the combination of inobrodib with bi-specific antibodies, as well as inobrodib in a maintenance setting.
Despite significant recent progress in treating multiple myeloma, the majority of patients still succumb to the disease. A large number of patients are not eligible for, or become resistant to, the latest therapies. Inobrodib’s truly novel mechanism of action, oral delivery, and favourable safety profile make it an attractive additional option. It has the potential to become an agent used across multiple settings, with different combination agents.
In 2023, the FDA granted Fast Track and orphan drug designation to inobrodib for treating relapsed or refractory multiple myeloma. Last year, CellCentric released promising efficacy and safety data at the American Society of Hematology (ASH) Annual Meeting. The company has achieved several significant milestones, including an initial $35 million investment from RA Capital last year as well as a $25 million strategic investment from Pfizer. This month, a new CellCentric office opened in Burlington MA, just outside Boston, as the company builds its team globally.
